Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 2013. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the GlaxoSmithKline 2009 Deferred Annual Bonus Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on share acquisition details.
- Share Price: 1,753 pence per Ordinary Share and $52.29 per American Depositary Share (ADS).
- Transaction Type: Increases in notional interests in Ordinary Shares and ADSs following the re-investment of dividends paid on July 11, 2013.
Material Changes
No material changes to financial performance or operational status are reported in this filing. The document details specific increases in notional shareholdings for various executives under the deferred bonus plan, including personal contributions and matching company contributions.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. It notes that notional dividends accrued will be paid out in proportion to the percentage of holdings that vest following the end of the relevant measurement period.
Investor Verification Points
- Verify the vesting schedule and measurement period for the 2009 Deferred Annual Bonus Plan to understand future payout obligations.
- Confirm the total number of shares and ADSs acquired by each named executive to assess alignment with company performance.
- Review the dividend reinvestment mechanism to ensure accurate calculation of notional interest increases.